+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Gemcitabine-based doublets for advanced non-small-cell lung cancer: beyond gemcitabine/cisplatin



Gemcitabine-based doublets for advanced non-small-cell lung cancer: beyond gemcitabine/cisplatin



Clinical Lung Cancer 3 Suppl 1: S10-S16



Gemcitabine is one of the most active agents in the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Recent evidence indicates that gemcitabine/cisplatin is among the most active doublets in advanced NSCLC, but the problem of what to give patients who cannot tolerate cisplatin still remains. The combination of gemcitabine/carboplatin is under investigation. Initially thought to be too myelosuppressive, recent schedule modifications have made this a more feasible doublet for NSCLC. Nonplatinum doublets consisting of gemcitabine with the taxanes or vinorelbine are also under investigation. This review covers the most current trials of gemcitabine-based doublets in advanced NSCLC.

(PDF emailed within 1 workday: $29.90)

Accession: 049140121

Download citation: RISBibTeXText

PMID: 14720349


Related references

Cisplatin/gemcitabine vs cisplatin/gemcitabine/vinorelbine vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine in advanced non-small cell lung cancer Final results of a Spanish lung cancer group phase III trial. European Journal of Cancer 37(Supplement 6): S28, October, 2001

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. Journal of Clinical Oncology 21(17): 3207-3213, 2003

A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin-gemcitabine chemotherapy (GFPC 03-01 Study). Journal of Thoracic Oncology 4(3): 364-370, 2009

A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer. Investigational New Drugs 30(3): 1144-1149, 2012

A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology 5(3): 159-168, 2013

Gemcitabine/docetaxel (GD) vs gemcitabine/cisplatin (GC) in stage IIIB/IV advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 24(18_suppl): 17017-17017, 2016

Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 23(16_suppl): 7329-7329, 2016

Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC). Ai Zheng 23(11 Suppl): 1455-1458, 2004

Gemcitabine-cisplatin vs gemcitabine-carboplatin in advanced non-small cell lung cancer A multicenter phase II randomized trial. European Journal of Cancer 37(Supplement 6): S50, October, 2001

Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 5(6): 427-428, 2002

Cisplatin-gemcitabine-vinorelbine vs cisplatin-vinorelbine vs cisplatin-gemcitabine in advanced non-small cell lung cancer Interim analysis of a SICOG phase III trial. European Journal of Cancer 35(SUPPL 4): S247, Sept, 1999

Interim analysis of a phase III trial comparing cisplatin, gemcitabine, and vinorelbine vs. either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non small-cell lung cancer. A Southern Italy Cooperative Oncology Group Study. Clinical Lung Cancer 1(3): 202-7; Discussion 208, 2004

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52(2): 155-163, 2006

Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 41(1): 81-89, 2003

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer 81(1): 77-83, 2014